News
-
-
PRESS RELEASE
Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
Catheter Precision announces VIVO interim results for VT localization at ESC Symposium, showcasing non-invasive mapping system accuracy in relation to myocardial scar in heart disease patients -
-
PRESS RELEASE
Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory
Catheter Precision, Inc. reveals first purchase order for LockeT suture retention device from a Chicago hospital within the Endeavor Health System, marking a significant milestone in US market expansion -
-
PRESS RELEASE
Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option
Catheter Precision, Inc. announces closing of public offering of common stock units and pre-funded warrant units. Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager -
-
PRESS RELEASE
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering
Catheter Precision, Inc. announces pricing of underwritten public offering of common stock units and pre-funded units, expecting $3.1 million gross proceeds. Details include warrants, offering conditions, book-running manager, and SEC registration -
-
PRESS RELEASE
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
Catheter Precision, Inc. releases Q2 Financials and Operational Report showcasing operational highlights and financial results. Company focuses on cardiac electrophysiology products VIVO and LockeT